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Abstract 
In their article on the cannabis debate, Strang et al raise the issue of cannabis and its effects on driving, 
suggesting that “a clearer understanding will be required of the extent to which a particular concentration 
of the drug (or its metabolites) can reliably be taken as evidence that an individual's driving ability was 
consequently impaired.” A review of the literature, however, suggests that defining an acceptable level of 
cannabis consumption for driving is unlikely to be possible for several reasons. 
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Length of penicillin treatment of streptococcal infections
Is seven days of treatment as effective as
10 days?
Editor—Zwart et al recommend seven days
of treatment for streptococcal infections as
opposed to three days.1 For several decades
we were educated to continue penicillin for
such cases for no fewer than 10 days.2 The
rationale was that streptococci must be
eradicated to prevent rheumatic fever and
that this was achievable only after 10 days of
treatment. This was based on bacteriologi-
cal, epidemiological, and clinical observa-
tions. The cost of oral penicillin is almost
negligible, and I think we need more
assurance to be persuaded to cut treatment
to only seven days. Is there any study that
will prove that treatment for seven days is as
effective as treatment for 10 days for
preventing rheumatic fever?
Dan Michaeli chairman, board of directors
Clalit Health Services, Tel Aviv 62098, Israel
michaeli@netvision.net.il
1 Zwart S, Sachs APE, Ruijs GJHM, Gubbels JW, Hoes AW, de
Melker RA. Penicillin for acute sore throat: randomised
double blind trial of seven days versus three days treatment
or placebo in adults. BMJ 2000;320:150-4. (15 January.)
2 Christie AB. Streptococcal infections—scarlet fever. In:
Christie AB. Infectious diseases: epidemiology and clinical prac-
tice. Edinburgh: Livingstone, 1969: 983.
Antibiotics should not be used for self
limiting illnesses
Editor—I have two concerns about Zwart
et al’s article1: firstly, the methodology, and,
secondly and more importantly, that it was
conceived at all, in view of the issue of
antibiotic use.
The study had an unusually high number
of exclusions (36.7%), and 26.6% of the
patients were not randomised. The secret
code of treatment was broken at the request
of the doctor or the patient. There was a faster
resolution in the patients in the seven day
treatment arm at two days than in the three
day treatment arm at two days, despite identi-
cal treatment, and I am not convinced by the
authors’ explanation. A possibility concern-
ing all the above points is that the randomisa-
tion was not successful, and therefore the
results of the trial may not be secure.
However, these doubts are minor com-
pared with the real issue, which is how we
use the precious resource of antibiotics.
Resistance to commonly used antibiotics is
rising fast.2 The increasing use of antibiotics
encourages resistant organisms in patients
and in the community.3 In most cases anti-
biotics do not prevent complications.4 5
Finally, antibiotics have at best mild to
modest benefit in pharyngitis.
If we continue to prescribe antibiotics
for self limiting illnesses where there is small
benefit at most, we will see an increase in the
incidence of serious resistant infections such
as pneumonia and meningitis, and in the
mortality inevitably associated with these
infections. Our resolution for the new
millennium should be to stop prescribing
antibiotics for minor self limiting conditions,
to allow nature to heal these, and to save
antibiotics for what they were designed for
in the first place—serious and life threaten-
ing disease.
R Fleetcroft GP principal
The Medical Centre, Hemsby, Norfolk NR29 4EW
rocdoc@user.scs-datacom.co.uk
1 Zwart S, Sachs APE, Ruijs GJHM, Gubbels JW, Hoes AW, de
Melker RA. Penicillin for acute sore throat: randomised
double blind trial of seven days versus three days treatment
or placebo in adults. BMJ 2000;320:150-4. (15 January.)
2 Johnson AP, Speller DCE, George RC, Warner M,
Domingue G, Efstratiou A. Prevalence of antibiotic
resistance and serotypes in pneumococci in England and
Wales: results of observational studies in 1990 and 1995.
BMJ 1996;312:1454-6.
3 Arason VA, Kristinsson KG, Sigurdsson JA, Stefansdottir
G, Molstad S, Gudmundsson S. Do antimicrobials increase
the carriage rate of penicillin resistant pneumococci in
children? Cross sectional prevalence study. BMJ
1996;313:387-91.
4 Howie JGR, Foggo BA. Antibiotics, sore throats, and rheu-
matic fever. J R Coll Gen Pract 1985;35:223-4.
5 Taylor JL, Howie JG. Antibiotics, sore throats and acute
nephritis. J R Coll Gen Pract 1983;33:783-6.
The data do not support the conclusions
Editor—Zwart et al conclude from a
placebo controlled randomised clinical trial
that seven days of penicillin treatment for
symptoms of acute sore throat is better than
three days of treatment.1 In the accompany-
ing editorial, one of the authors of the
Cochrane review on antibiotics for sore
throats (8 hours’ benefit) is puzzled by the
anomalous trial data that are presented.2
As shown in figures 1 and 2 in Zwart et
al’s paper, the two primary outcome
measures, resolution of symptoms and reso-
lution of impaired daily activities, do not
support those conclusions. The Kaplan-
Meier plots show that at day 3 the resolution
of symptoms in group 1 (seven days of peni-
cillin) and group 2 (three days of penicillin)
was significantly different, although both
groups had received identical treatment.
This unexplained twofold difference
between the two penicillin groups carries
over to misleading conclusions at day 7.
Importantly, outcomes in group 2 were
almost identical with those for group 3 (pla-
cebo) for the entire study period.
The following results emerge by simply
reformulating the research question as: what
is the benefit of an additional four days of
penicillin treatment, after the initial three
days? From figure 1, in the seven day and
three day groups, patients who were free of
symptoms from day 3 through to day 7 were
37% v15%; 50% v 25%; 70% v 43%; 80% v
55%; and 88% v 63% (thus differences in
rates of cure are 22%, 25%, 27%, 25%, and
25%, respectively). As additional treatment
in group 1 starts after day 3, when this point
is taken as the baseline reference the relative
benefits are 3%, 5%, 3%, and 3% for days 4
through 7. Similarly, the other primary out-
come measure, resolution of impaired activ-
ity (figure 2), shows relative benefits of −2%,
3%, −1%, and 3%, indicating no cumulative
benefits from the extra four days of
penicillin.
The authors need to explain the anoma-
lous cure rate advantages for patients in
group 1 at the day 3 baseline. My prime sus-
pect is the unaccounted differences in prog-
nostic factors such as “sore throat days” at
entry among the three treatment groups,
perhaps inadvertently favouring the seven
day group. Also, use of well defined disease
duration (onset, entry, and resolution) in life
Advice to authors
We prefer to receive all responses electronically,
sent either directly to our website or to the
editorial office as email or on a disk. Processing
your letter will be delayed unless it arrives in an
electronic form.
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intention is to post all other electronic
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table analyses may clarify these puzzling
results.
Because the findings show equivalence
of placebo to three days of penicillin in
treating symptoms of acute sore throats, I
see no reason for the Cochrane review of
Del Mar and colleagues to be revised.3
Erdem I Cantekin professor of otolaryngology
University of Pittsburgh, School of Medicine,
Children’s Hospital of Pittsburgh, Pittsburgh, PA
15213, USA
lac32@juno.com
1 Zwart S, Sachs APE, Ruijs GJHM, Gubbels JW, Hoes AW, de
Melker RA. Penicillin for acute sore throat: randomised
double blind trial of seven days versus three days treatment
or placebo in adults. BMJ 2000;320:150-4. (15 January.)
2 Del Mar C. Sore throats and antibiotics. BMJ
2000;320:130-1. (15 January.)
3 Del Mar C, Glasziou PP. Do antibiotics shorten the illness
of sore throat? In: Cochrane Collaboration. Cochrane
Library. Issue 3. Oxford: Update Software, 1996.
Life tables should be used with caution
Editor—Both Fleetcroft and Cantekin
point out a curious anomaly in life table
analysis of recovery from acute illness. If the
outcome measure chosen is the day on
which symptoms last occurred rather than
the end of the period of continuous
symptoms, the kind of pattern observed in
Zwart et al’s study is almost unavoidable.1
Imagine two patients—Bob in the seven
day group and Paul in the three day group.
Both get better after 24 hours, but Paul
relapses on day 5 and recovers on day 7. On
the life table Bob seems to have recovered in
the crucial first three days whereas Paul does
not. Hence the early takeoff of the recovery
curve in the seven day group. It does not in
any way indicate allocation bias between the
groups.
Perhaps the lesson is that life tables
should be used with caution for data of this
kind.
Peter Burke tutor in general practice
St Bartholomew’s Medical Centre, Oxford
OX4 1XB
pdb@ermine.ox.ac.uk
1 Zwart S, Sachs APE, Ruijs GJHM, Gubbels JW, Hoes AW, de
Melker RA. Penicillin for acute sore throat: randomised
double blind trial of seven days versus three days treatment
or placebo in adults. BMJ 2000;320:150-4. (15 January.)
Care must be taken when extrapolating
data
Editor—The high prevalence of Centor cri-
teria, fever, and quinsy (1:60 untreated) in
Zwart et al’s patients1 compared with
patients from an unselective trial (1:400) or
routine data2 3 confirms that pre-trial selec-
tion probably occurred, but details of
pre-selection are a little unclear.
The severity of symptoms is not pre-
sented. Analgesic use was similar in the trial
groups until day 4. Symptom relief after
this—when symptoms are milder—may not
be clinically important. This is supported by
the lack of difference in time off school and
work. The estimated 1-2 days’ benefit must
also be put in the context of the much larger
data set from the systematic review—
suggesting a benefit of 8 hours to half a day.4
Perhaps the most important finding is
that quinsy may be prevented. The
Cochrane review4 relies heavily (76% of the
weight) on a study of hospitalised patients
given parenteral penicillin, where quinsy
was common (1:18)—that is, not generalis-
able. The Centor criteria are crude because
they were validated against the throat swab.
Nevertheless, the current trial supports
the finding of another trial5 that crude
antibiotic targeting to a clinical subgroup
may prevent quinsy. However, since most
patients were unwell with fever, targeting
clinical subgroups may be no better than the
general practitioner’s overall judgment that
the patients are not unwell systemically:
these patients are at low risk irrespective of
clinical signs—20% of the 716 patients had
three out of four Centor criteria, and the
only patient who developed quinsy did not
fulfil the Centor criteria.2 3
Care must be taken in extrapolating effi-
cacy trials to effectiveness in routine settings.
Tablet counting and repeated examination
may improve compliance, thus altering esti-
mates of efficacy. With regard to symptoms,
in an effectiveness trial (no repeated
examination or tablet counting) patients
with a very similar cluster to the Centor cri-
teria, but who were well systemically, showed
a benefit from antibiotics of a fraction of a
day.2 With regard to complications, the com-
puterised notes for five years in two
contrasting practices documented nine
cases of quinsy after presentation to the doc-
tor: six received penicillin—so, preventing
100% of quinsy after sore throat, as implied
by the efficacy trial results of Zwart et al and
Dagnelie et al,5 is perhaps unlikely in every-
day practice.
The results of Zwart et al’s study must be
put in the context of the presenting popula-
tion, other evidence, and the possible
difficulties of generalising evidence from
efficacy trials to effectiveness in routine
settings.
Paul Little MRC clinician scientist
ps13@soton.ac.uk
Ian Williamson senior lecturer
Community Clinical Sciences (Primary Medical
Care Group), University of Southampton,
Aldermoor Health Centre, Southampton
SO15 6ST
Greg Warner general practitioner
Nightingale Surgery, Romsey SO51 7QN
Michael Moore general practitioner
Three Swans Surgery, Salisbury SP1 1DX
1 Zwart S, Sachs APE, Ruijs GJHM, Gubbels JW, Hoes AW, de
Melker RA. Penicillin for acute sore throat: randomised
double blind trial of seven days versus three days treatment
or placebo in adults. BMJ 2000;320:150-4. (15 January.)
2 Little PS, Williamson I, Warner G, Gould C, Gantley M,
Kinmonth AL. An open randomised trial of prescribing
strategies for sore throat. BMJ 1997;314:722-7.
3 Little PS, Gould C, Williamson I, Warner G, Gantley M,
Kinmonth AL. Reattendance and complications in a
randomised trial of prescribing strategies for sore throat:
the medicalising effect of prescribing antibiotics. BMJ
1997;315:350-2.
4 Del Mar C, Glaziou P. Antibiotics for the symptoms and
complications of sore throat. In: Cochrane Collaboration.
Cochrane Library. Issue 3. Oxford: Update Software, 1998.
5 Dagnelie CF, Van der Graf Y, De Melker R, Touw-Otten
FWMM. Do patients with sore throat benefit from penicil-
lin? A randomised double blind placebo controlled clinical
trial with penicillin V in general practice. Br J Gen Pract
1996;46:589-93.
Authors’ reply
Editor—Michaeli comments on the risk of
rheumatic fever when prescribing penicillin
for fewer than 10 days. Indeed, in areas with
poorer living conditions than in the Nether-
lands, a 10 day course of penicillin is needed.
The distribution of the T/M subtypes of
group A streptococci among our patients
and among healthy controls will be pub-
lished shortly. Rheumatogenic subtypes
were cultured in patients as well as in
controls.1
We were surprised by the difficulties
experienced by Fleetcroft, Cantekin, and
also by Del Mar in his editorial,2 concerning
the methodological question of how to
present the resolution of symptoms when
they recurred during the first week of obser-
vation. A survival analysis gave us the most
realistic picture of any difference in duration
of symptoms between the treatment groups.
Unfortunately, the results from the three day
penicillin group (with 40% recurrences in
the first week) had to be forced into the
Kaplan-Meier straitjacket by using the
definition of permanent resolution of symp-
toms. We do not agree with Cantekin’s
interpretation of our findings as we chose
the endpoint of permanent resolution of
symptoms. Burke’s comments support our
earlier explanation.
Little and colleagues focus on the gener-
alisability of the results, which is the most
relevant issue of any clinical trial. Indeed, the
21% of patients who did not meet the
required number of clinical criteria was
lower than the 50-60% rate we expected
from the results of a previous study in the
Netherlands.3 Probably the participating
general practitioners underreported the
number of patients with sore throats who
were not eligible “at first sight.”
We agree with Little et al that we studied
a selected population. However, this was our
intention. We tried to mimic the general
practitioner’s daily practice of patient selec-
tion. In this way, we were not surprised to
find that penicillin was more effective than in
Little et al’s population, which probably
included many patients with a viral infec-
tion.4 Interestingly, Little et al’s open trial
also included a subgroup of 94 ill patients
with a symptom-sign complex similar to our
complete patient group. Their table 3
indicates that antibiotics reduced the dura-
tion of sore throat in these patients.
Unlike Little et al, we are not worried
that the artificial use of throat swabs and
medication tray biased the recording of
symptoms in the diary. How can this bias
play a role if randomised patient groups are
compared? Our trial was not designed to
study whether penicillin would prevent
quinsy or peritonsillar cellulitis.
Nevertheless, the reason that the protective
effect of penicillin in our patient group
seemed to be at the same level as in some
studies in the 1950s may again be explained
by the strict inclusion criteria we used,
selecting probably the most ill patients, most
of them having a throat swab that was posi-
tive for streptococci.
Letters
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We agree with Little et al that the popu-
lation studied should be taken into account
when the findings are generalised. However,
because we found important and relevant
effects of penicillin, we feel free to reverse
the association between result and popula-
tion. To incite further discussion on the
management of sore throat in adults we
therefore recommend for other routine set-
tings, such as the primary care setting in the
United Kingdom, the selection criteria that
we used in our study and that are also used
in Dutch daily practice.
Fleetcroft and Little et al fear that
penicillin will be used as a routine drug in a
routine setting, thus leading to medicalised
patients and resistant strains. We share their
fear, but believe that doctors and patients
can make a well balanced decision only
when they are informed not only about the
costs and adverse effects of antimicrobial
treatment, but also about the benefits.5
Sjoerd Zwart general practitioner
Alfred Sachs general practitioner
Arno Hoes professor of clinical epidemiology
Ruut de Melker professor of general practice
Julius Center for General Practice and
Patient-oriented Research, University Medical
Center Utrecht, 3584 CG Utrecht, Netherlands
Gijs Ruijs clinical microbiologist
Laboratory for Microbiology and Infectious
Diseases, Isala Clinics, 8021 AM Zwolle,
Netherlands
Jan Gubbels statistician
Organisation for Advice on Research and
Policymaking, 5361 JZ Grave, Netherlands
1 Zwart S, Ruijs GJHM, Sachs APE, van Leeuwen WJ,
Gubbels JW, de Melker RA. Beta-hemolytic streptococci
isolated from acute sore throat patients: cause or
coincidence? A case-control study in general practice.
Scand J Infect Dis 2000 (in press).
2 Del Mar C. Sore throats and antibiotics. BMJ
2000;320:130-1. (15 January.)
3 Dagnelie CF, Touw-Otten FWMM, Kuyvenhoven MM,
Rozenberg-Arska M, de Melker RA. Bacterial flora in
patients presenting with sore throat in Dutch general
practice. Fam Pract 1993;10:371-7.
4 Little PS, Gould C, Williamson I, Warner G, Gantley M,
Kinmonth AL. An open randomised trial of prescribing
strategies for sore throat. BMJ 1997;314:722-7.
5 Graham A, Fahey T. Sore throat: diagnostic and therapeu-
tic dilemmas. BMJ 1999;319:173-4.
Treating children with sleep
disorders
Children with breathing difficulties are
being overlooked
Editor—I was disappointed to see that once
again children with sleep disorders are
being lumped into a homogeneous group of
children with “behavioural” problems, then
‘‘studied” without using polysomnography. I
think it’s presumptuous and dangerous to
think that every child who has trouble sleep-
ing has a behavioural problem. Few physi-
cians are aware that breathing difficulty can
cause night waking and bedtime resistance,
and it is because of studies like that of Ram-
chandani et al.1
Doctors don’t look for sleep disorders
properly, don’t know much about them, and
are told repeatedly that behavioural treat-
ments are the appropriate treatment. This is
wrong unless we can guarantee that the chil-
dren have behavioural problems. A study
looking at obese children using polysomno-
graphy diagnosed unsuspected obstructive
sleep apnoea in 75% of the children
studied—meaning the physicians examining
the children picked up only 1 in 4 cases. It
therefore seems a big leap of faith not to be
doing polysomnography more often. Some
of the children waking at night could have
upper airways resistance syndrome, which
can also cause sleep problems. Most doctors
can barely take a proper history for sleep
disorders, let alone diagnose a subtle case of
upper airways resistance syndrome causing
repeated night waking or bedtime resist-
ance. Studies like that of Ramchandani et al
certainly don’t help because they take the
emphasis away from finding a “real physi-
ological” problem and on to stress behav-
ioural modification.
Before we continue to send physicians
out to behaviourally modify breathing
difficulties or other subtle causes of sleep
disorders that can mimic behavioural prob-
lems, we need to do polysomnography on
these children.
Mary Fay general paediatrician
2303 Glenview Avenue, Park Ridge, IL 60068, USA
mfay@enteract.com
1 Ramchandani P, Wiggs L, Webb V, Stores G. Systematic
review of treatments for settling problems and night wak-
ing in young children. BMJ 2000;320:209-13. (22 January.)
Night waking is natural behaviour
Editor—The basic assumption of the study
of Ramchandani et al that very young
children should settle down to sleep away
from their parents and not be seen or heard
from again until morning is flawed.1 In many
non-Western societies this type of sleep pat-
tern would be seen as an aberration.
Anthropologist Carol Wortham of
Emory University in Atlanta uncovered a
variety of sleep patterns in 10 traditional
hunter-gatherer societies, none of which
coincide with our society’s current ideal of
sleeping alone without waking alone for the
entire night.2 Perhaps some amount of night
waking in children and their desire for com-
forting by parents are both natural and
healthy. Our difficulty in combating this
behaviour may arise because we are
struggling against nature and basic human
biology. We must be careful not to confuse
that which is desirable for human health
with that which is merely a current
preference and expectation of our society.
Zan Buckner breast feeding counsellor
4294 Shihmen Drive, Antioch, TN 37013, USA
1 Ramchandani P, Wiggs L, Webb V, Stores G. Systematic
review of treatments for settling problems and night wak-
ing in young children. BMJ 2000;320:209-13. (22 January.)
2 Wothman CM, Melby MK. Toward a comparative develop-
mental ecology of human sleep. In: Carskadon MA, ed.
Adolescent sleep patterns: biological, social, and psychological
influences. New York: Cambridge University Press (in press).
Early intervention increases sleep times
in young babies
Editor—Ramchandani et al’s systematic
review of treatments for established infant
sleep problems shows that behavioural
interventions improve sleep patterns.1 The
authors reference the frequency of sleep dis-
orders as 20% in children aged 1-3 years, the
tendency for these problems to be persist-
ent, and their associations with behavioural
difficulties and family disharmony. Other
authors quote the frequency of sleep distur-
bance to be as high as 35%.2 Armstrong
reported that 60% of parents were getting
up at night when their child was 12 months
old, and half of them were rising three times
a night or more.3
We tested the impact of a short behav-
ioural intervention in normal neonates in a
randomised trial (submitted for publication).
In all, 269 families with normal newborn sin-
gletons were recruited within the first three
weeks of life and were randomly allocated to
intervention or control groups. Families in
the intervention group received a single 45
minute tutorial from a research nurse. The
tutorial emphasised that in children who
were healthy and gaining weight satisfactorily
sleep achievement should be regarded as a
“learnt skill” influenced by environmental
factors or “cues of sleep.” Parents were
encouraged to avoid fatigue in their infants
by not overhandling and to establish cues of
sleep independent of the parent. Outcomes
were measured through a sleep diary at 6
weeks of age.
All aspects of sleep performance were
significantly improved in the intervention
group. Total sleep increased by almost nine
hours a week at 6 weeks (P < 0.0001). The
proportion of infants sleeping 15 hours a
day was 61% in the intervention group and
28% among controls (P < 0.0001). 78% of
sleep cycles among infants in the interven-
tion group included over eight hours of
night sleep, compared with 61% of cycles
among controls (P < 0.0001).
Although the technique emphasised
minimising parental handling at sleep time,
there was no difference in the amount of
crying between the groups. Follow up at 3
months of age showed that improvements
were maintained. Our findings therefore
support, and add to, those reported in the
systematic review.
Although Ramchandani et al did a well
designed systematic review, our unpublished
work was not identified, and it would be
unreasonable to expect it to have been. This
experience therefore supports the calls for a
register of planned and ongoing ran-
domised trials,4 and it also shows the
importance of regularly updating systematic
reviews through the Cochrane Collabora-
tion as new evidence becomes available.
Brian Symon senior lecturer
bsymon@medicine.adelaide.edu.au
John Marley professor of general practice
Department of General Practice, University of
Adelaide, South Australia
James Martin director of respiratory medicine
Adelaide Women’s and Children’s Hospital
Adelaide, South Australia
1 Ramchandani P, Wiggs L, Webb V, Stores G. Systematic
review of treatments for settling problems and night wak-
ing in young children. BMJ 2000;320:209-13. (22 January.)
2 Johnson MC. Infant and toddler sleep. A telephone survey
of parents in one community. Dev Behav Pediatrics
1991;12:108-14.
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3 Armstrong KL, Quinn RA, and Dadds MR. The sleep pat-
terns of normal children. Med J Aust 1994;161:202-6.
4 Horton R, Smith R. Time to register randomised trials.
BMJ 1999;319: 865-6. (2 October.)
Treatment of child sleeping problems
and the quality of trials are important
Editor—Ramchandani et al’s finding that
behavioural treatments are effective in treat-
ing sleep problems will inform practice but
omitted three important issues.1
Firstly, two of the nine identified treat-
ment studies included infants as young as 1
month. Infants are not born with the ability to
sleep through the night, but sleep patterns
are entrained by environmental cues.2 Wak-
ing at night in the early months of life is an
adaptive behaviour to secure frequent feed-
ing and to allow for rapid weight gain and
brain growth. Sleeping through the night in
the early weeks of life and a lack of waking for
feeds is likely to put vulnerable infants (such
as preterm infants or poor feeders) at risk of
poor appetite development and suboptimal
growth.3 Behavioural treatments for night
waking should thus not start before 6 months
of age.
Secondly, infants who are breast fed do
sleep less during 24 hours4 and are more
likely to wake at night than bottle fed
infants.3 Parents should be informed that
breast feeding does not impede infants from
learning to sleep through the night. Early
routines, avoidance of feeding the infant
into “sleep submission,” and the use of focal
feeds can, however, help to reduce the stress
of night time breast feeding.
Thirdly, sleeping problems often coexist
with excessive crying or feeding difficulties.2
Parents with infants with multiple difficulties
are more likely to seek help. Studies are still
required to establish that behavioural inter-
ventions are effective in infants with multiple
problems.
Finally, quality criteria developed for
drug trials were used to judge the quality of
the behavioural treatments.1 These include
double blinding to guard against perform-
ance bias and randomisation to exclude
selection bias. Double blinding is not
possible in behavioural studies. Therapists
have to know what they are doing and why.
Randomisation in small samples (less than
30) is often not effective as the effect sizes
may become inflated because of outliers and
there may be pretreatment differences.
Quality ratings are there to judge the
internal validity of a trial—that is, the
confidence that the cause of any observed
differences is due to the treatment condi-
tions. The increasing use of “off the shelf”
criteria for judging the quality of behav-
ioural treatments is of doubtful validity.
There are specific methods to guard against
performance bias in behavioural trials such
as the investigation of generalised placebo
effects. Checking and controlling for a range
of pretreatment differences may be as
important as randomisation itself.5
Dieter Wolke research professor of psychology
Department of Psychology, University of
Hertfordshire, Hatfield AL10 9AB
D.F.H.Wolke@herts.ac.uk
1 Ranchandani P, Wiggs L, Webb V, Stores G. A systematic
review of treatments for settling problems and night wak-
ing in young children. BMJ 2000;320:209-13. (22 January.)
2 Wolke D, Meyer R, Ohrt B, Riegel K. Co-morbidity of cry-
ing and feeding problems with sleeping problems in
infancy: concurrent and predictive associations. Early Dev
Parenting 1995;4:191-207.
3 Wolke D, Söhne B, Riegel K, Ohrt B, Österlund K. An epi-
demiological study of sleeping problems and feeding
experience of preterm and fullterm children in south Fin-
land: comparison to a south German population sample. J
Pediatrics 1998;133:224-31.
4 Lucas A, St James-Roberts I. Crying, fussing and colic
behaviour in breast- and bottle-fed infants. Early Hum Dev
1998;53:9-18.
5 Lipsey MW, Wilson DB. The efficacy of psychological, edu-
cational, and behavioural treatment. Am Psychologist
1993;48:1181-209.
Authors’ reply
Editor—We are aware of Fay’s general point
that it is the underlying sleep disorder rather
than the presenting complaint at which
treatment should be directed. She suggests
that polysomnography is indicated for all
children presenting with a sleep problem.
We consider it more important that careful
clinical inquiry is made to identify children
with wide ranging physical conditions or
other sleep disorders associated with sleep
disturbance rather than to focus on the few
conditions that can be identified by
polysomnography. Furthermore, the appro-
priate diagnostic criteria for paediatric sleep
related breathing disorders are being fre-
quently refined (adult criteria, which have
been used in the past, are not appropriate),
and polysomnography is just one of the
clinical investigations that may be required
to diagnose these conditions.1
All but one of the studies in our review
(one study did not explicitly state screening
procedures) included a broad assessment of
the children’s overall sleep pattern and
medical history, including careful screening
for symptoms suggestive of other sleep
disorders and medical conditions. In the
absence of any clinical signs of sleep related
breathing disorders, and with clear indica-
tion of behavioural aspects maintaining the
child’s sleep problem, it would be difficult to
justify (both to parents and to healthcare
providers) the need for potentially unhelp-
ful polysomnographic assessment.
Fay suggests that waking at night and
bedtime resistance may themselves be a
clinical sign of a sleep related breathing dis-
orders, arguing that a large proportion of
children with obstructive sleep apnoea also
have such problems. This link is contentious
and disputed,1 and, even if it is accepted it
does not follow that a large proportion of
children with night waking and bedtime
resistance also have obstructive sleep
apnoea. The prevalence figures make it
more likely that children with obstructive
sleep apnoea form a small subset of those
with behavioural sleeplessness. Research
suggests that a detailed sleep history would
alert clinicians to which patients are likely to
fall into this group.1 A phased approach to
both assessment and treatment is needed to
ensure maximum diagnostic accuracy and
to minimise unnecessary procedures.2
Buckner is right that assumptions about
children’s sleep are culturally determined.
However, the reality that parents and health-
care professionals face within a Western
society is that it is often considered desirable
for children to sleep independently. In this
context continuing sleep disturbance in a
young child has many adverse effects on
both the child and his or her parents or car-
ers. Given this, seeking the best ways of help-
ing such parents or carers find solutions to
their difficulty seems a reasonable pursuit.
We agree with Symon et al that a register
of planned and ongoing trials, and the
updating of systematic reviews through the
Cochrane Collaboration are important. We
have had discussions with the Cochrane
Collaboration to that end. Nevertheless,
their study would not have been included in
our review as we focused on children with an
established sleep problem. Another system-
atic review has dealt with studies similar to
theirs.3
We agree with the first three points
made by Wolke. His fourth, about the choice
of quality criteria, identifies a dilemma
facing anyone conducting a systematic
review: should they describe each study and
its strengths and weaknesses in detail or use
a quality rating scale as a form of shorthand?
Within a journal it is rarely possible to
describe each study in detail, and it can also
make for difficult reading. The use of quality
criteria makes comparison of trials easier to
understand, but at the cost of inevitable loss
of accuracy. We would welcome the develop-
ment of quality criteria more appropriate
for psychological treatment trials. Until that
time use of well standardised quality ratings4
represents the best compromise.
Luci Wiggs research psychologist
Gregory Stores professor
University of Oxford Section of Child and
Adolescent Psychiatry Park Hospital for Children,
Oxford OX3 7LQ
Paul Ramchandani specialist registrar
Child and Family Psychiatric Service, Sue Nicholls
Centre, Manor House, Aylesbury HP20 1EG
Vicky Webb general practitioner
Florence Nightingale House, Aylesbury HP21 8AL
1 Carroll JL, Loughlin GM. Obstructive sleep apnea
syndrome in infants and children: clinical features and
pathophysiology. In: Ferber R, Kryger M, eds. Principles and
practice of sleep medicine in the child.Philadelphia: W B Saun-
ders, 1995:163-91.
2 Stores G. Practitioner review: assessment and treatment of
sleep disorders in children and adolescents. J Child Psychol
Psychiatry 1996;37:907-25.
3 Renfrew MJ, Lang S. Influencing the sleep patterns of
exclusively breastfed infants. In: Cochrane Collabortion.
Cochrane Library. Oxford: Update Software, 1994.
4 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds
DJM, Gavaghan DJ, et al. Assessing the quality of reports of
randomized clinical trials: is blinding necessary? Control
Clin Trials 1996;17:1-12.
Recent advances in intensive
care
Percutaneous tracheostomy may not be
more effective than open technique
Editor—In his review of recent advances in
intensive care Stott emphasised the efficacy
of percutaneous tracheostomy over the con-
ventional open surgical approach.1 We agree
that percutaneous tracheostomy may indeed
be the preferred method in selected cases,
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but it is invariably not used in patients who
present anatomical challenges such as a
short, thick neck; goitre; a history of neck
surgery; or a concurrent coagulopathy. Such
difficult cases probably represent about a
quarter of an average population requiring
tracheostomy.
We disagree with Stott’s assertion that the
incidence of complications has been shown
to be lower with percutaneous tracheostomy
than with open surgical techniques. The
paper quoted in support of this
statement—by Hill et al—describes the results
of 356 percutaneous procedures performed
in a single unit over four years.2 No direct
comparison is made with open tracheosto-
mies, and the authors do not report the num-
bers and type of patients deemed unsuitable
for percutaneous tracheostomy and referred
for open procedures. The six previous
independent series quoted that detailed com-
plication rates for open tracheostomy were
published on average nearly 20 years earlier,
and a conclusion was reached by comparison
with these older studies.
Stott fails to mention Dulguerov et al’s
meta-analysis reported in 1999, which
showed that percutaneous tracheostomy is
associated with a higher prevalence of
certain complications.3 Their comparison of
recent surgical tracheostomy trials (n = 21;
3512 patients) and percutaneous tracheos-
tomy trials (n = 27; 1817 patients) shows that
perioperative complications are more com-
mon with the percutaneous technique (10%
v 3%), whereas postoperative complications
occur more often with the surgical tech-
nique (10% v 7%). The bulk of the
differences is in minor complications, except
perioperative death (0.44% v 0.03%) and
serious cardiorespiratory events (0.33% v
0.06%), which were much higher with the
percutaneous technique. These authors also
noted significantly fewer complications in
recent studies compared with older ones.
In the present state of knowledge it
would seem unethical to mount a large dou-
ble blind trial comparing the two techniques
as this would subject about a quarter of
patients, who would usually be deemed
unsuitable for a percutaneous technique, to
an increased risk of complications. It is likely
that such patients will continue to be
referred for open tracheostomy. While this
selection bias continues, it is misguided to
state that percutaneous tracheostomy holds
fewer risks than the open technique.
Natalie Brookes specialist registrar
David Howard senior lecturer
Royal National Throat, Nose and Ear Hospital,
London WC1X 8DA
1 Stott S. Recent advances in intensive care. BMJ
2000;320:358-61. (5 February.)
2 Hill BB, Zweng TN, Maley RH, Charash WE, Toursarkiss-
ian B, Kearney PA. Percutaneous dilatational tracheos-
tomy: report of 356 cases. J Trauma 1996;41:238-43.
3 Dulguerov P, Gysin C, Perneger TV, Chevrolet JC. Percuta-
neous or surgical tracheostomy: a meta-analysis. Crit Care
Med 1999;27:1617-25.
Author’s reply
Editor—Brookes and Howard’s point that
not all patients are suitable for a percutane-
ous tracheostomy is well made, but the
figure quoted of 25% is conjecture and not
referenced. As I cannot find any data to pro-
duce a figure of my own I will not, but I do
question their final paragraph when they
state that because of this figure a double
blind trial would be unethical. This is curious
as nowhere in my article did I suggest that
one should be performed.
The meta-analysis referenced looks only
at studies published up to 1996 and
compares four different percutaneous tech-
niques with surgical tracheostomies per-
formed in two different eras.1 As most of the
deaths occurring with percutaneous trache-
ostomy occur with a non-dilatational tech-
nique it would seem prudent to exclude
these from the analysis.
There have been three published pro-
spective trials comparing dilatational percu-
taneous tracheostomy with open surgical
techniques.2–4 These show complication rates
for percutaneous tracheostomy to be as low
as or lower than those for the surgical tech-
nique. This, coupled with the reduced cost,
avoidance of moving critically ill patients,
and low long term complication rates,
means that I can still conclude that percuta-
neous tracheostomy is a significant recent
advance.
Stephen Stott consultant in anaesthesia and intensive
care
Grampian University Hospitals Trust, Aberdeen
AB25 2ZN
s.a.stott@abdn.ac.uk
1 Dulguerov P, Gysin C, Perneger TV, Chevrolet JC. Percuta-
neous or surgical tracheostomy: a meta-analysis. Crit Care
Med 1999;27:1617-25.
2 Hazard P, Jones C, Benitone J. Comparative clinical trial of
standard operative tracheostomy with percutaneous
tracheostomy. Crit Care Med 1991;19:1018-24.
3 Crofts SL, Alzeer A, McGuire GP, Wong DT, Charles D. A
comparison of percutaneous and operative tracheosto-
mies in intensive care patients. Can J Anaesth 1995;42:
775-9.
4 Friedman Y, Fides J, Mizock B, Samuel J, Patel S, Appavu S,
et al. Comparison of percutaneous and surgical tracheos-
tomies. Chest 1996;110:480-5.
More still needs to be known about
immunonutrition
Editor—I have concerns over one section in
Stott’s article on recent advances in intensive
care.1 These concerns relate to the para-
graphs on nutrition, and particularly the key
points box on page 358; there it is stated that
recent work has shown that omega 3
polyunsaturated fatty acids improve mor-
tality in critical illness.
The question of immunonutrition is
complex, and the different nutrients used in
clinical trials can have different, and
opposing, effects on the immune system. For
example, L-arginine and glutamine stimu-
late a variety of immune functions.2 In
contrast, omega 3 and omega 6 fatty acids
inhibit a variety of immune functions.2 3
The timing of administration of these
nutrients may therefore be critically impor-
tant: although it is generally believed that
stimulation of the immune system is benefi-
cial in critically ill patients, this may not always
be the case. For example, in certain patients
(those with adult respiratory distress syn-
drome or multiorgan failure) in whom the
cytokine cascade and production of inflam-
matory mediators has been suggested to be
excessive, administration of omega 3 and
omega 6 fatty acids would be beneficial in
reducing production of these mediators.
In terms of immunonutrition affecting
clinical outcome in critical illness, a recent
critical analysis of all the randomised
controlled trials in which L-glutamine was
given found little evidence to support its
routine clinical use.4 A recent meta-analysis
found that giving combinations of immuno-
modulatory nutrients reduced infectious
complications but not mortality.5
When the use of nutrition in critically ill
patients is being considered, these consid-
erations must be taken into account. It is still
not clear which patients will benefit from
being fed these immunomodulatory nutri-
ents and which may not.
Steven D Heys professor of surgical oncology and
nutritional oncology
University of Aberdeen, Aberdeen AB24 3UX
s.d.heys@abdn.ac.uk
1 Stott S. Recent advances in intensive care. BMJ
2000;320:358-61. (5 February.)
2 Heys SD, Gough DB, Khan L, Eremin O. Nutritional phar-
macology and malignant disease: a therapeutic modality.
Br J Surg 1996;83:608-19.
3 Almallah YZ, El-Tahir A, Heys SD, Richardson S, Eremin
O. Distal procto-colitis and n-3 polyunsaturated fatty acids:
the mechanism(s) of natural cytotoxicity inhibition. Eur J
Clin Invest 2000;30:58-65.
4 Heys SD, Ashkanani F. Glutamine. Br J Surg 1999;86:289-
90.
5 Heys SD, Walker LG, Smith I, Eremin O. Enteral
nutritional supplementation with key nutrients in patients
with critical illness and cancer: a meta-analysis of
randomized controlled clinical trials. Ann Surg
1999;229:467-77.
Genetic factors and
osteoporotic fractures in
elderly people
Twin data support genetic contribution to
risk of fracture
Editor—Kannus et al suggest from pro-
spective data collected on Finnish twins that
genetic factors are of only minor
importance in explaining the population
occurrence of osteoporotic fracture, particu-
larly in women.1
The evidence given to support this is the
relatively small excess in concordance in
monozygotic twins compared with dizygotic
twins. But it is well recognised that twin
concordances may be misleading unless the
underlying prevalence of a disease is taken
into account.2 For example, a small absolute
differenceinmonozygoticcomparedwithdizy-
gotic concordance is more suggestive of a
genetic effect for a trait that is relatively rare
(such as fracture) than for one that is com-
mon. The data thus warrant closer scrutiny.
We have estimated the relative contribu-
tion of genetic, shared environmental, and
unique environmental components to the
variation in susceptibility to fracture in these
twins from the data provided. The analysis
was conducted using a variance components
approach with the statistical software Mx.3
The method assumes that risk of fracture is
determined by a continuous underlying
liability and is a plausible assumption for
this trait.4
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As expected, the results show significant
evidence of familial resemblance in the risk of
fracture in both male and female twins. In
female twins, despite the nationwide sam-
pling frame, there is insufficient statistical
power in this study to distinguish between
models containing components in which this
clustering is attributed to genetic factors
alone, the shared family environment of the
twins, or the combination of the two. In a
model in which the only contribution is from
geneticanduniqueenvironmentalfactors,gen-
etic factors account for 36% of the variance in
the liability to fracture at any body site.
In male twins the familial resemblance is
explained by a significant contribution from
genetic factors but not by the shared family
environment, with genetic factors account-
ing for 35% of the variation in liability to
fracture. A greater genetic contribution is
also suggested at the spine in table A in
Kannus et al’s study (bmj.com/cgi/content/
full/319/7221/1334/DC1), although infer-
ence is limited by the small numbers of
concordant pairs and the lack of data on dif-
ferences between the sexes in rate of
fracture. In contrast to the conclusion
reached by the authors, these data show that
genetic factors contribute to a third of the
liability to osteoporotic fracture in men and
are entirely compatible with the hypothesis
that genetic factors contribute to a similar
extent in women. The data suggest that
there may be differences in the nature of the
genetic risk in men and women and at
different body sites that merit further study.
Alex J MacGregor Arthritis Research Campaign
senior fellow
alex.macgregor@kcl.ac.uk
Harold Snieder genetic epidemiologist
Tim D Spector director
Twin Research and Genetic Epidemiology Unit, St
Thomas’s Hospital, London SE1 7EH
1 Kannus P, Palvanen M, Kaprio J, Parkkari J, Koskenvuo M.
Genetic factors and osteoporotic fractures in elderly
people: prospective 25 year follow up of a nationwide
cohort of elderly Finnish twins. BMJ 1999;319:1334-7. (20
November.)
2 Smith C. Concordance in twins: methods and interpret-
ation. Am J Hum Genet 1974;26:454-66.
3 Neale MC. Mx: statistical modeling. 4th ed. Richmond, VA:
Department of Psychiatry (Box 126 MCV, Richmond, VA
23298, USA), 1997.
4 Falconer DS. Introduction to quantitative genetics. Harlow:
Longman Scientific and Technical, 1989.
Study supports possibility of differences
in development of osteoporotic fractures
between sexes
Editor—Kannus et al report their large,
long term prospective study analysing the
genetic predisposition of osteoporotic frac-
tures in elderly Finnish twins.1 It is important
to note that whereas the concordance rate
for fractures was indeed not strikingly differ-
ent between monozygotic and dizygotic twin
pairs in women, there was a fourfold
difference in men.
In their electronic response to the article
[published here in the paper journal, above]
MacGregor et al have estimated the relative
contribution of genetic components on the
basis of the data provided; they found a
strong role for genetic factors in men but
not women.2 Previous studies have pointed
to possible differences in the main regula-
tory factors in the development of low bone
mineral density and osteoporotic fractures
between the sexes. We suggest that the data
presented by Kannus et al could be
interpreted as further evidence supporting
this hypothesis.
Bone density is suggested to be multi-
factorially regulated and polygenically deter-
mined. Underlying diseases such as inflam-
matory bowel disease and several drugs such
as glucocorticosteroids can modulate and
enhance the effect of genetic factors on the
development of osteoporotic fractures. For
example, our studies have shown that the
allele 2 at the AvaI polymorphism in the
interleukin-1 â gene—related to a higher pro-
duction of the cytokine—is associated with a
subgroup of patients (those with the non-
fistulising form of Crohn’s disease).3 Addi-
tionally, we have found a strong correlation
between this polymorphism and bone min-
eral density in patients with inflammatory
bowel diseases but not in healthy controls. We
also found a difference between the two sexes:
the association at the lumbar spine was
present only in men.4
Bone loss at the cortical and trabecular
bones seems to be influenced by several
physiological and other elements such as the
menopause or use of corticosteroids. There-
fore, analysing data after screening for the
often “silent” vertebral fractures could further
modify Kannus et al’s results concerning the
importance of the genetic background.
Bone mineral density is a key predictor
of osteoporotic fractures. To judge the
weight of genetic influence it would be
important to compare concordance rates in
the groups with low and high Z score values.
We suggest that studies in well defined
subgroups of patients may help to define
those conditions in which genetic back-
ground has a high prognostic value for the
risk of osteoporotic fractures.
Andrea Nemetz assistant research assistant
Semmelweis University of Medicine, 2nd
Department of Medicine, Budapest 1088, Hungary
Amado Salvador Pena professor of gastrointestinal
immunology
Free University Hospital, Amsterdam, Netherlands
as.pena@azvu.nl
1 Kannus P, Palvanen M, Kaprio J, Parkkari J, Koskenvuo M.
Genetic factors and osteoporotic fractures in elderly
people: prospective 25 year follow up of a nationwide
cohort of elderly Finnish twins. BMJ 1999;319:1334-7. (20
November.)
2 MacGregor AJ, Snieder H, Spector TD. Twin data support
a genetic contribution to fracture risk [electronic response
to Kannus et al. Genetic factors and osteoporotic fractures
in elderly people: prospective 25 year follow up of a
nationwide cohort of elderly Finnish twins]. bmj.com
1999. www.bmj.com/cgi/eletters/319/7221/1334#EL1
(accessed 5 April).
3 Nemetz A, Nosti-Escanilla MP, Molnár T, Köpe A, Kovács
A, Fehér J, et al. IL1B gene polymorphisms influence the
course and severity of inflammatory bowel disease.
Immunogenetics 1999;49:527-31.
4 Nemetz A, Zágoni T, Tóth M, Kovács A, Nosti-Escanilla MP,
García-González MA, et al. Interleukin-1 gene polymor-
phisms stimulate bone loss in inflammatory bowel
diseases. Gut 1999;45(suppl V):A15.
Authors’ reply
Editor—On the basis of our published data
MacGregor et al computed estimates of
genetic variance in liability to osteoporotic
fractures. Our original manuscript had the
same modelling analysis (table), but after a
recommendation by a reviewer and the
BMJ’s editorial committee we omitted the
modelling part of the study from the paper.
MacGregor et al’s interpretation of the
results of the modelling differs from ours.
We emphasise three points. Firstly, no matter
what model is used to examine our data, the
liability to osteoporotic fracture has a large
environmental component (always >60%)
in both sexes. This is not clearly pointed out
by MacGregor et al.
Secondly, we do not want to say that
“genetic factors are of only minor
importance in explaining the population
occurrence of osteoporotic fracture”; we
want to say that they are not strongly related
to it. We thus want to draw attention to the
fact that although genetic factors have a
dominant role in explaining interindividual
variation in bone density, the result is quite
different (that is, unshared environmental
effects become dominant) when the end
point is changed from bone tissue to
fractures, the true end point of the entire
osteoporosis problem.
Thirdly, in women MacGregor et al
highlight the AE model (the only contribu-
tion to risk of fracture is from genetic and
unique environmental factors), in which
Model fitting for data on osteoporotic fractures among monozygotic and dizygotic twin pairs of Finnish
twin cohort
Model
Proportion of variance accounted for by:
÷2 value P value
Akaike’s
information
criterion*
Additive
genetic
effects (A)
Non-additive
genetic
effects (D)
Shared
environmental
effects (C)
Unique
environmental
effects (E)
Men
E 1.000 15.28 0.009 5.28
CE 0.216 0.784 7.22 0.13 −0.78
AE 0.347 0.653 3.28 0.51 −4.72
ACE 0.347 0.000 0.653 3.28 0.35 −2.72
ADE 0.000 0.398 0.602 1.83 0.61 −4.17
Women
E 1.000 26.68 0.00 8.44
CE 0.260 0.740 0.57 0.97 −7.44
AE 0.367 0.633 1.35 0.85 −6.45
ACE 0.146 0.168 0.686 0.10 0.99 −5.91
ADE 0.367 0.000 0.633 1.35 0.72 −4.65
*Combines information on statistics of goodness of fit (the lower the ÷2 value the better the fit) and simplicity of model (the
best model usually being the one with the lowest value).
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genetic factors account for about 36% of the
variance in liability to fracture, but they
ignore the fact that the CE model (includes
no genetic effects to explain twin similarity
in liability to fracture) gave a better fit to the
data. It has to be remembered that the statis-
tical power of the study was not sufficient to
differentiate between these competing
explanations. Clearly, more incident cases
are needed for more definitive conclusions.
Finally, we agree with MacGregor et al
that there may well be differences in the
nature of the genetic risk of osteoporotic
fracture between men and women and at
different body sites. Further follow up of our
cohort and examination of the situation in
other populations are thus needed.
With regard to Nemetz and Pena’s letter,
analysis of “silent” vertebral fractures will not
change the result of the clinically more
important non-vertebral fractures. We do
not fully agree with the authors’ statement
that bone density is a key predictor of
osteoporotic fractures. Many recent epi-
demiological studies indicate that falling is
the strongest single predictor of these
fractures, and bone mineral density is an
independent predictor of only moderate
importance. When this fact becomes more
widely recognised, the framework of fracture
prevention will become shifted more
appropriately—towards preventing falls in
elderly people.
Pekka Kannus chief physician
Accident and Trauma Research Centre, UKK
Institute, PO Box 30, FIN-33501 Tampere, Finland
klpeka@uta.fi
Jaakko Kaprio professor
Department of Public Health and General Practice,
University of Oulu, FIN-90220 Oulu, Finland
Markku Koskenvuo professor
Department of Public Health, University of Turku,
FIN-20520 Turku, Finland
Mika Palvanen research fellow
Accident and Trauma Research Centre, UKK
Institute, PO Box 30, FIN-33501 Tampere
Jari Parkkari chief physician
Research Centre of Sports Medicine, UKK Institute,
PO Box 30, FIN-33501 Tampere
Improving the debate on
cannabis
Let’s find out whether cannabis has
therapeutic value
Editor—In discussions of the use of canna-
bis one of the biggest problems over the past
few years has been the difficulty in separating
the debate on the recreational use from that
on the therapeutic use. The article by Strang
et al also mixes the two issues.1
In all my years of working in pain relief I
cannot remember the equivalent mix-up tak-
ing place over cocaine, morphine, heroin, etc.
Although some matters occasionally overlap,
the two main elements of the cannabis debate
must remain in separate arenas. Only then
can we educate politicians and the public
about the facts and the real issues.
Meanwhile, let’s get on and find out
whether cannabis has significant and valu-
able therapeutic potential. This agent has
been used medicinally for 5000 years and
we still don’t know whether it is therapeuti-
cally effective.
William Notcutt consultant anaesthetist
James Paget Hospital, Great Yarmouth NR31 6LA
willy@tucton.demon.co.uk
1 Strang J, Witton J, Hall W. Improving the quality of the
cannabis debate: defining the different domains. BMJ
2000;320:108-10. (8 January.)
Consider public welfare, not just public
health
Editor—Strang et al raise a number of sali-
ent issues in the debate over whether canna-
bis should be legalised.1 However, the eight
“domains of the cannabis debate” identified
are centred exclusively on a public health
conception of the relevant policy issues.
Although this is understandable given the
audience that the authors are addressing,
they fail to consider more fundamental
issues of what the public policy objectives
should be when considering the recreational
use of cannabis.
Their discussion reflects the fact that the
medical profession has a natural tendency to
judge the public regulation and legal control
of activities according to their impact on the
health of the public. Thus, anything shown
to be harmful to health is seen as inherently
bad, while activities that promote health are
seen as something to be encouraged by
public institutions.
An alternative vision of the objective of
public intervention and legislative structures
is that they should exist to protect and
improve public welfare as distinct from pub-
lic health. Individual welfare is clearly
affected by health but it also encompasses a
broader class of personal benefits that
people enjoy when freely undertaking
specific activities (including using cannabis),
even in cases in which they are knowingly
exposing themselves to possible health risks.
This “welfarist” angle should not be con-
fused with the libertarian line, which would
espouse the removal of legal barriers that
prevent people having the freedom to do as
they wish. In the welfarist paradigm public
regulation and control will always be
required if the use of cannabis affects the
welfare (including the health) of parties who
are outside the decision to use. Public inter-
vention is also needed to ensure that users
are informed of any risks associated with
use, even if this means telling people that at
present the risks are largely unknown.
If it is accepted that health is only one
aspect of individual welfare and that it is the
responsibility of government to promote
individual welfare even if in certain
instances this means compromising health,
then a public health driven debate will never
offer satisfactory guidance on the desirabil-
ity of the legal status quo of cannabis use.
Andrew Healey research officer
Department of Social Policy, London School of
Economics and Political Science, London
WC2A 2AE
A.T.Healey@lse.ac.uk
1 Strang J, Witton J, Hall W. Improving the quality of the
cannabis debate: defining the different domains. BMJ
2000;320:108-10. (8 January.)
Social context should be added to
domains being considered
Editor—Strang et al argue that the canna-
bis debate has been oversimplified into
polarised positions that consider cannabis to
be either generally harmless and potentially
therapeutic or harmful to health and conse-
quently deserving of prohibition.1 To
improve the quality of debate the authors
usefully identify eight domains within which
the health effects of cannabis should be
examined. However, these domains repre-
sent only a narrow biological view of this
difficult issue and focus almost exclusively
on examining potentially negative effects.
Further overarching domains, in particular
of social context, need to be added to the
debate.
Social opportunity costs arise as a result
of criminalising cannabis users. These
include their exclusion from school, univer-
sity, and employment; incarceration; and
blighting of their lives and careers as conse-
quences of their becoming involved with
criminal subcultures. Furthermore, cannabis
use should be considered against the health
consequences of alternative drugs, such as
alcohol, which compete within a similar
social niche. Current ethics do not provide
an even handed assessment of alcohol—the
drug of choice of large numbers of older
people—and cannabis—the drug of choice
of many younger people. Testing alcohol
against Strang et al’s domains is an informa-
tive exercise.
At the other end of the drug spectrum,
cannabis legislation ties up disproportionate
amounts of police and other judicial time. In
1998, of the 2240 police incidents directly
involving drugs in Merseyside, 70.8% related
to cannabis while heroin incidents
accounted for only 6.3%.2 Consequently, the
cost of current cannabis legislation also
includes the diversion of judicial efforts away
from drugs that have enormous repercus-
sions for health.
Perhaps we can now begin to have an
objective, evidence based, and inclusive dis-
cussion of the whole topic of alcohol and
drug abuse, which includes tobacco, and
which takes a social administration perspec-
tive in looking at the costs and benefits of
social policy in full rather than being narrow-
ly concerned with selective biological aspects.
John R Ashton regional director of public health
NHS Executive North West, Warrington WA3 7QN
Mark A Bellis head of public health
Public Health Sector, Liverpool John Moores
University, Liverpool L3 2AB
m.a.bellis@livjm.ac.uk
1 Strang J, Witton J, Hall W. Improving the quality of the
cannabis debate: defining the different domains. BMJ
2000;320:108-10. (8 January.)
2 Hardi L, Bellis MA. Merseyside interagency drug misuse data-
base: a unified approach to drug misuse data. Liverpool:
Molyneux, 1999.
The effects of cannabis on driving are
difficult to evaluate
Editor—In their article on the cannabis
debate, Strang et al raise the issue of canna-
bis and its effects on driving, suggesting that
“a clearer understanding will be required of
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the extent to which a particular concentra-
tion of the drug (or its metabolites) can reli-
ably be taken as evidence that an individual’s
driving ability was consequently impaired.”1
A review of the literature, however, suggests
that defining an acceptable level of cannabis
consumption for driving is unlikely to be
possible for several reasons.
Firstly, there is a poor correlation
between plasma concentrations of trans-Ä-
tetrahydrocannabinol (THC) (the constituent
of cannabis responsible for the production of
most of the psychoactive response) after
smoking and subjective, self reported psycho-
logical effects; plasma concentrations of THC
decline long before peak effects are felt.2 Sec-
ondly, the relation between psychological test-
ing and performance in experiments of real
driving is complex because the two modali-
ties of testing are different. Impairment in
driving has been shown experimentally with
acute intoxication by cannabis3; however,
attempts to correlate driving performance
with concentrations of THC will be severely
affected by the observed time lag between
THC concentrations and peak effects.
The issue is further complicated in
people who use cannabis heavily for
prolonged periods. This group has been
shown to develop tolerance to the somatic
and psychological effects of THC; this toler-
ance cannot be correlated with any drop in
concentration below that of users who are
not tolerant.4 Chronic heavy users of canna-
bis do, however, show subtle impairment in
memory, organisation, and attention, and
the effect becomes more pronounced the
longer the duration of use.5 Whether these
effects diminish the ability to drive is not
clear, but since they are unrelated to acute
intoxication, it is unlikely that it will ever be
possible to correlate them with concentra-
tions of THC. Furthermore, it is not clear
whether these abnormalities are reversible
with prolonged abstinence.
The pursuit of a definition of a “safe”
amount of cannabis that can be consumed
and still allow for driving is unlikely to be
successful.
Sarah Levy registrar in toxicology
Alison Jones consultant toxicologist
National Poisons Information Service (London),
Medical Toxicology Unit, London SE14 5ER
sarah.levy@gstt.sthames.nhs.uk
1 Strang J, Witton J, Hall W. Improving the quality of the
cannabis debate: defining the different domains. BMJ
2000;320:108-10. (8 January.)
2 Perez-Reyes M, DiGuiseppi S, Davis KH, Schindler VH,
Cook CE. Comparison of effects of marijuana cigarettes of
three different potencies. Clin Pharmacol Ther 1982;131:
617-24.
3 Smiley A. Marijuana: on road and driving simulator stud-
ies. In: Kalant H, Corrigal W, Hall W, Smart R, eds. The
health effects of cannabis. Toronto: Addiction Research
Foundation, 1998.
4 Hunt CA, Jones RT. Tolerance and disposition of tetra
hydro cannabinol in man. J Pharmacol Exper Ther
1980;215:35-44.
5 Solowij N. Cannabis and cognitive functioning. Cambridge:
Cambridge University Press, 1998.
Emergency admissions in
Stockport were exaggerated
Editor—Morgan et al say that the increase
in emergency admissions in Avon from
1989 to 1998 may be an artefact.1 Analyses
in the annual public health report for Stock-
port reached a similar, but not identical,
conclusion.2
We found that the increases were
exaggerated. Information distortions, inter-
hospital transfers, increasing rates of admis-
sion for minor conditions, and changed
patterns of flow affecting a particular provider
unfairly accounted for almost two thirds of
the apparent increase, leaving a true under-
lying pressure of 2.5% a year. Part of this
increase was explained by changed practice—
for example, improved management of chest
pain—and part was unexplained.
The unexplained increase was entirely
among elderly people. A rapid response
scheme for acute care at home was put in
place jointly by health and social services.
For the first six months that the scheme was
in place there was no year on year increase
in emergency admissions for the population
of Stockport. Since our original response
last year,3 however, this halt has not been
sustained and the pattern of emergency
admissions has shifted towards younger age
groups. This shift has not yet been fully
analysed.
Patterns of emergency admission are
complex. They require active management
but this must not simply assume a constantly
rising pressure. Investment in community
services is relevant to a whole system
approach.
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Number of embryos allowed in
fertility treatment should be
flexible
Editor—The Royal College of Obstetri-
cians and Gynaecologists’ new guidelines for
the management of infertility in tertiary
care1–3 are generally welcomed. Guideline
10, however, recommends that the maxi-
mum number of embryos should be
reduced from three to two for all patients.
This is an imprecise way of dealing with a
complex problem, eliminating triplets at the
expense of some couples having their own
child. Regulatory authorities already deprive
some women of having their own children
because of the decision to fix the upper limit
to three in 1987. The college should have
evaluated who is at risk of having a multiple
pregnancy and made recommendations
based on this risk.
A fertility index based on factors associ-
ated with the risk of having a multiple preg-
nancy could be calculated to determine how
many embryos to transfer. This should result
in women with high reproductive potential
receiving one or two embryos and those
with low reproductive potential receiving
three or even more. We have indirect
evidence to support this reasoning. Using
gamete intrafallopian transfer, we have
transferred more than three eggs to women
aged > 40 who have a low risk of multiple
pregnancy; this technique does not come
under the supervision of the Human Fertili-
sation and Embryology Authority. Our live
births/ongoing pregnancies for those aged
41-44 is 15%, compared with about 4.8%
from the authority’s national data on in vitro
fertilisation, and there were no triplets.
We believe that the college’s recommen-
dation is flawed. If transferring two rather
than three embryos in women aged <40
gives the same chance of a singleton
pregnancy there should be a comparable
singleton pregnancy rate between centres
with different incidences of two embryo
transfers. Analysis of data from the Human
Fertilisation and Embryology Authority for
all ages in 1999 indicates very different rates
between our centre (12% two embryo trans-
fer) and centres having a higher incidence—
for example, Aberdeen (63%) and Hammer-
smith Hospital (52%).2 The differences were
not simply due to an increase in multiple
pregnancy—mostly twin pregnancies. The
chance of having a birth per embryo
transfer for all treatments, including the use
of frozen embryos, was greater in our centre
(19.5% compared with 14.4% and 12.5%
respectively); the chance of a singleton birth
was 13.3% compared with 11.1% and 9.9%.
Guideline 10 also states erroneously that
there is a significant risk of triplets in women
over 40 when three embryos are transferred,
but the Human Fertilisation and Embryol-
ogy Authority’s data indicate just one set in
808 transfers. The college should acknowl-
edge that infertile women have different
reproductive potentials and risks of multiple
pregnancy; it should amend its recommen-
dation to allow for flexibility rather than
have patients fit an inappropriate and incor-
rect medicopolitical dogma.
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